[go: up one dir, main page]

TR201808283A2 - Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ - Google Patents

Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ Download PDF

Info

Publication number
TR201808283A2
TR201808283A2 TR2018/08283A TR201808283A TR201808283A2 TR 201808283 A2 TR201808283 A2 TR 201808283A2 TR 2018/08283 A TR2018/08283 A TR 2018/08283A TR 201808283 A TR201808283 A TR 201808283A TR 201808283 A2 TR201808283 A2 TR 201808283A2
Authority
TR
Turkey
Prior art keywords
ethenersept
composition
water pharmaceutical
agent
pharmaceutical composition
Prior art date
Application number
TR2018/08283A
Other languages
English (en)
Inventor
Çakar Güni̇z
Karban Özgür
Pavia Claudio
Ignacio Amadeo Gabriel
Valeria Mauro Laura
Paola Zuqueli Romina
Barreras Maximo
Belén Bosco Maria
Orti Eduardo
Guillermina Forno Ángela
Original Assignee
Centurion Ilac San Ve Tic A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centurion Ilac San Ve Tic A S filed Critical Centurion Ilac San Ve Tic A S
Priority to TR2018/08283A priority Critical patent/TR201808283A2/tr
Priority to PCT/TR2018/050302 priority patent/WO2019240690A1/en
Publication of TR201808283A2 publication Critical patent/TR201808283A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu buluş, deri altı enjeksiyon yoluyla uygulanan anti-tümör nekroz faktörü (TNF) maddesini içeren bir sulu farmasötik bileşim ile ilgilidir. Buluşa ait farmasötik bileşim ayrıca bir stabilizatör, bir ozmotik ajan, bir izotonik ajan ve tampon çözelti gibi bir veya daha fazla yardımcı madde içermektedir.
TR2018/08283A 2018-06-11 2018-06-11 Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ TR201808283A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2018/08283A TR201808283A2 (tr) 2018-06-11 2018-06-11 Sulu farmasöti̇k etenersept bi̇leşi̇mi̇
PCT/TR2018/050302 WO2019240690A1 (en) 2018-06-11 2018-06-12 Aqueous pharmaceutical composition of etanercept

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2018/08283A TR201808283A2 (tr) 2018-06-11 2018-06-11 Sulu farmasöti̇k etenersept bi̇leşi̇mi̇

Publications (1)

Publication Number Publication Date
TR201808283A2 true TR201808283A2 (tr) 2018-07-23

Family

ID=64605615

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/08283A TR201808283A2 (tr) 2018-06-11 2018-06-11 Sulu farmasöti̇k etenersept bi̇leşi̇mi̇

Country Status (2)

Country Link
TR (1) TR201808283A2 (tr)
WO (1) WO2019240690A1 (tr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
WO2014011629A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept

Also Published As

Publication number Publication date
WO2019240690A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
EA202090410A1 (ru) АГОНИСТЫ Toll-ПОДОБНОГО РЕЦЕПТОРА 7 (TLR7), ИМЕЮЩИЕ ПИРИДИНОВЫЙ ИЛИ ПИРАЗИНОВЫЙ ФРАГМЕНТ, ИХ КОНЪЮГАТЫ, ПРИМЕНЕНИЯ И СПОСОБЫ С НИМИ
CL2021003233A1 (es) Sistemas de casx artificiales
EA202092003A1 (ru) Соединения для лечения болезни гентингтона
CO2022001590A2 (es) Inhibidores de parp1
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CR20210578A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunotaria indeseable
NI201900112A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CY1124493T1 (el) Υγρη φαρμακευτικη συνθεση
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CO2020001930A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
PH12019550249A1 (en) Solid compositions for oral administration
EA201691478A1 (ru) Новый полисахарид и его применения
MX2021015761A (es) Polipeptidos.
EA202091398A1 (ru) Составы вакцинных композиций от вируса денге
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
MX2020007384A (es) Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112021000899A2 (pt) Peptídeos de ligação a il-17a e usos médicos dos mesmos
EA201992272A1 (ru) Ацилированное инсулиновое соединение
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico